Emily Harrold

Emily Harrold

Auto-generated profile, based on publicly available information

Emily Harrold

Department of Medical Oncology, St James’s Hospital, D08 NHY1 Dublin, Ireland

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 October 2025 in Clinical Cancer Research
Verified
Journal Article
Open access
CYCeline Yeh
Celine Yeh
OAOliver Artz
Oliver Artz
HZHaochen Zhang
Haochen Zhang
EKElias-Ramzey Karnoub
Elias-Ramzey Karnoub
PNPeter Ntiamoah
Peter Ntiamoah
RYRona Yaeger
Rona Yaeger
Purpose: Microsatellite stable (MSS) colorectal cancers, in contrast to microsatellite instability–high colorectal cancers, have few mutations and are insensitive to immune checkpoint blockade (ICB). Colorectal cancers treated with targeted agents often acquire a high number of genomic alterations at progression. We asked whether targeted therapy could be used to generate a high tumor mutational burden (TMB) in MSS colorectal cancer and sensitize these tumors to ICB. Experimental Design: In patients with MSS metastatic colorectal cancer treated with targeted therapy, we evaluated baseline and progression TMB and response to ICB for patients whose tumors developed high TMB. We determined types of alterations, mutational signatures, neoantigenicity, and clonality associated with emergent genomic alterations in cases of acquired high TMB. Results: Among 26 cases, nine acquired high TMB at progression. Three of these patients received ICB but none had a response. In the TMB-high cases, we found no induction of tumor-infiltrating lymphocytes or PD-L1 expression. Acquired genomic alterations consisted predominantly of single-nucleotide variants, were enriched for single base substitution 17a/b mutational signature, and did not enhance predicted MHC class I binding. TMB was higher in plasma, driven by highly subclonal acquired alterations, compared with tissue samples, which harbored few resistance alterations. Conclusions: A substantial number of MSS colorectal cancers acquire high TMB following targeted therapy. However, this change is not associated with sensitization to ICB. The high TMB is due to subclonal alterations unique to individual disease sites that are inadequate to elicit a robust antitumor immune response. See related commentary by Parseghian and Eluri, p. 999

20 May 2016 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
LPLisa Mary Prior
Lisa Mary Prior
EHEmily Harrold
Emily Harrold
COConnor Gerard O'Leary
Connor Gerard O'Leary
KNKillian Nugent
Killian Nugent
JGJack Patrick Gleeson
Jack Patrick Gleeson
CKCatherine Kelly
Catherine Kelly
E14534 Background: Checkpoint inhibitors have been shown to improve survival outcomes in patients with metastatic malignant melanoma. However, the use of these agents is associated with a unique spectrum of immune related toxicities. Despite this, durable responses on immunotherapy are still possible even in patients who experience grade 3 toxicities. Furthermore, trials to date have shown that steroids do not appear to affect survival. We present the long term data on real world toxicities and response rates for patients treated previously with Ipilimumab at a national academic cancer centre. Methods: All patients treated previously with Ipilimumab at our centre were identified from pharmacy records. We performed a retrospective paper and electronic review and extracted relevant demographic data (age, sex) and clinical data (number of cycles, incidence and grade of immune related adverse events, interruption/cessation of therapy, need for immunosuppression, initial response to treatment and time to progression). Results: 33 patients with metastatic malignant melanoma were treated with Ipilimumab at our centre from 2011 to 2016. The incidence of G1, G2 and G3 toxicities was 33% (n = 11), 6% (n = 2) and 29% (n = 9), respectively. 23% (n = 7) of patients required steroids and 6% (n = 2) required TNF-a inhibitors. Treatment was stopped in 23% of patients due to Grade 3 toxicites. Of the grade 3 toxicities, colitis was the most common (46%, n = 6). In addition, rare toxicities were idenfied including orbital myositis (1 patient) and myelitis (1 patient). The response rate in the patient subset that required steroids was 42% vs. 15% in those that did not. The median duration of response in those that required and did not require steroids was 8 and 7 months respectively. Conclusions: Higher response rates and a longer median duration of response was seen in patients with grade 3 toxicities requiring steroids. The incidence of toxicities may reflect increased immunotherapy activity, thus leading to superior response rates. Further studies are needed to assess if earlier use of steroids to mitigate toxicities and the possibility of "treating through toxicities" could lead to increased efficacy of these agents in the future.

19 March 2024 in Clinical Cancer Research
Verified
Journal Article
Open access
PDF file
EHEmily Harrold
Emily Harrold
FKFergus Keane
Fergus Keane
HWHenry Walch
Henry Walch
JCJoanne F. Chou
Joanne F. Chou
JSJenna Sinopoli
Jenna Sinopoli
RYRona Yaeger
Rona Yaeger
Purpose: Targeted therapies have improved outcomes for patients with metastatic colorectal cancer, but their impact is limited by rapid emergence of resistance. We hypothesized that an understanding of the underlying genetic mechanisms and intrinsic tumor features that mediate resistance to therapy will guide new therapeutic strategies and ultimately allow the prevention of resistance. Experimental Design: We assembled a series of 52 patients with paired pretreatment and progression samples who received therapy targeting EGFR (n = 17), BRAF V600E (n = 17), KRAS G12C (n = 15), or amplified HER2 (n = 3) to identify molecular and clinical factors associated with time on treatment (TOT). Results: All patients stopped treatment for progression and TOT did not vary by oncogenic driver (P = 0.5). Baseline disease burden (≥3 vs. <3 sites, P = 0.02), the presence of hepatic metastases (P = 0.02), and gene amplification on baseline tissue (P = 0.03) were each associated with shorter TOT. We found evidence of chromosomal instability (CIN) at progression in patients with baseline MAPK pathway amplifications and those with acquired gene amplifications. At resistance, copy-number changes (P = 0.008) and high number (≥5) of acquired alterations (P = 0.04) were associated with shorter TOT. Patients with hepatic metastases demonstrated both higher number of emergent alterations at resistance and enrichment of mutations involving receptor tyrosine kinases. Conclusions: Our genomic analysis suggests that high baseline CIN or effective induction of enhanced mutagenesis on targeted therapy underlies rapid progression. Longer response appears to result from a progressive acquisition of genomic or chromosomal instability in the underlying cancer or from the chance event of a new resistance alteration.

13 June 2025 in JNCI: Journal of the National Cancer Institute
Verified
Journal Article
Closed access
FKFergus Keane
Fergus Keane
LSLily V Saadat
Lily V Saadat
COCatherine A O’cOnnor
Catherine A O’cOnnor
JCJoanne F Chou
Joanne F Chou
ABAnita S Bowman
Anita S Bowman
Eileen O'ReillyEileen O'Reilly
Eileen O'Reilly
Background: The utility of circulating tumor DNA (ctDNA) in addressing challenges of molecular tissue profiling and complementing next-generation sequencing is undefined in pancreas ductal adenocarcinoma. The objective of this study was to assess ctDNA detection rates by stage, disease burden, and metastasis patterns; compare overall survival between ctDNA-positive and ctDNA-negative patients cases; and determine concordance between ctDNA and matched-tissue biopsies. Methods: Patients with pancreas ductal adenocarcinoma who had undergone Next Generation Sequencing by the MSK-ACCESS (Memorial Sloan Kettering – Analysis of Circulating cfDNA to Evaluate Somatic Status) ctDNA assay between 2019 and 2022 were included. Clinical and survival data were abstracted from a prospectively maintained clinical database. Results: A total of 414 patients with pancreas ductal adenocarcinoma: 28% stage I-II, 21% stage III, 51% stage IV. ctDNA detection was highest among patients with advanced disease: 75% stage IV, 38% stage III, 34% stage I-II disease. For stage IV, ctDNA was more frequently detected in patients with at least 2 organs involved vs with less than 2 organs involved (76% vs 38%, P = .025). Higher rates of ctDNA detection were observed in patients with liver metastases vs without (82% vs 52%, P < .001). In the untreated stage IV cohort (n = 120), median overall survival was 10 months for those with detectable ctDNA (95% CI = 6.9 to 14 months) vs 19 months (95% CI = 13 months to not reached) for those with undetectable ctDNA (P = .1). Concordance between ctDNA and matched tissue next-generation sequencing was lower in untreated stage I-III disease, but high for untreated stage IV pancreas ductal adenocarcinoma, including a critical success index of 93.1% of KRAS variants. Conclusion: ctDNA is a promising tool in the detection of somatic variants in pancreas ductal adenocarcinoma. Concordance between ctDNA and tissue is high for patients with untreated metastatic disease, notably for detection of KRAS variants.

26 October 2024 in JNCI: Journal of the National Cancer Institute
Verified
Journal Article
Closed access
PDF file
FKFergus Keane
Fergus Keane
COCatherine O’cOnnor
Catherine O’cOnnor
DMDrew Moss
Drew Moss
JCJoanne F Chou
Joanne F Chou
MPMaria A Perry
Maria A Perry
Eileen O'ReillyEileen O'Reilly
Eileen O'Reilly
Adjuvant mFOLFIRINOX (mFFX) is standard of care for fit individuals with resected pancreatic ductal adenocarcinoma (PDAC). There are limited data on adjuvant mFFX outcomes outside clinical trials. Institutional databases queried to identify patients with resected PDAC who received ≥1 dose adjuvant mFFX. Primary endpoints: recurrence free survival (RFS), overall survival (OS). Secondary endpoints: clinical factors, genomic features associated with outcomes. RFS and OS were estimated with Kaplan-Meier. Cox proportional hazards regression model was used to associate clinico-genomic features correlated with survival outcomes. N = 147 identified between 01/2015–01/2023. Median age: 67 years; N = 57 (39%) >70 years. Unfavorable prognostic features: N = 52 (36%) N2 nodal status, N = 115 (78%) lymphovascular invasion), and N = 133 (90%) perineural invasion. Median time from surgery to start mFFX: 1.78 months (m) (IQR 1.45, 2.12). N = 124 (84%) completed 12 doses; N = 98 (67%) stopped oxaliplatin early for neuropathy (median 10 doses; range 4-12). Further dosing characteristics are summarized in Supplementary Table 3. With median follow up of 35.1 m, median RFS (mRFS) 26 m (95% CI 19, 39) and median OS (mOS) not reached. For >70 cohort, mRFS 23 m (95% CI 14, NR) and mOS 51 m (95% CI 37, NR). mFFX started 70 years.

21 November 2025 in Current Oncology
Verified
Journal Article
Open access
PDF file
RGRichard Grainger
Richard Grainger
TTTatiana S. Temperley
Tatiana S. Temperley
HTHugo C Temperley
Hugo C Temperley
BCBen Creavin
Ben Creavin
EHEmily Harrold
Emily Harrold
MKMichael Eamon Kelly
Michael Eamon Kelly
Background: Colorectal cancer (CRC) mainly affects older adults, yet elderly patients are underrepresented in outcomes research. Accurate risk stratification tools, such as the Charlson Comorbidity Index (CCI), are essential for guiding surgical decisions in this group. Methods: We conducted a retrospective review of patients aged 75 years or older who underwent colorectal cancer resection at a tertiary centre between January 2019 and September 2024. Clinical, pathological, and molecular data were analyzed. The primary outcome was a composite of major postoperative complications (Clavien–Dindo grade 3 or higher) or 30-day mortality, stratified by CCI (5 or higher vs. less than 5). Statistical tests included chi-square, Fisher’s exact, and Mann–Whitney U as appropriate. Results: The median age was 81 years (range 75–97), with 59.7% male. CCI ≥ 5 was observed in 24.6% (51/211). The primary composite outcome of major postoperative complications or 30-day mortality occurred in 15/51 (29.4%) patients with a CCI ≥ 5 compared to 19/160 (11.9%) with a CCI < 5 (p = 0.04). Major complications occurred in 18.5% (39/211) of cases, and the 30-day mortality rate was 3.3% (7/211). Laparoscopic resection was independently protective in multivariate analysis (adjusted OR 0.37, p = 0.048), while age ≥85 and emergency presentation were not statistically significant predictors. Conclusions: Colorectal resection in patients aged ≥75 is linked with acceptable morbidity and low short-term death rates. A CCI ≥ 5 significantly predicts adverse outcomes and should be included in preoperative assessments. Minimally invasive surgery seems advantageous and should be considered, when possible, to enhance results in this high-risk group.